Press release content from Globe Newswire. The AP news staff was not involved in its creation.
CMS Proposes Additional Payment for Shockwave’s Coronary IVL in Hospital Inpatient Cases
Shockwave Medical, Inc.April 28, 2021 GMT
SANTA CLARA, CALIF., April 27, 2021 (GLOBE NEWSWIRE) Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the Centers for Medicare and Medicaid Services (CMS) published the Fiscal Year 2022 Hospital Inpatient Prospective Payment System (IPPS) Proposed Rule, which recommended that coronary IVL cases be eligible for incremental payment via a New Technology Add-On Payment (NTAP) from CMS when performed in the hospital inpatient setting. The proposed annual rule is now open for public comment and is expected to be finalized and in effect by October 1, 2021.
(Photo by Alex Wong\Getty Images)
The Centers for Medicare and Medicaid Services has updated the Medicare fee-for-service payment rates and policies for inpatient hospitals and long-term care hospitals for 2022.
Before taking into account Medicare disproportionate share hospital payments and Medicare uncompensated care payments, the proposed increase in operating payment rates, increases in capital payments, increases in payments for new medical technologies, increases in payments due to implementation of the imputed floor and other proposed changes will increase hospital payments in FY 2022 by $3.4 billion, or 2.8%.
But there is much in the proposed rule beyond payment updates.
The proposed rule would require hospitals to report vaccination rates among healthcare staff. CMS is proposing the adoption of the COVID-19 Vaccination Coverage among Healthcare Personnel Measure to require hospitals to report COVID-19 vaccinations of workers in their facilities.
(Photo by Tom Werner/Getty Images)
Today Viz.ai, an artificial intelligence care coordination company, shared the closing of its Series C funding round worth $71 million.
Scale Venture Partners and Insight Partners led the financing with participation from Greenoaks, Kleiner Perkins, Threshold Ventures, CRV, Innovation Endeavors and Susa Ventures.
This latest round comes about a year and a half after its $50 million Series B raise. To date, Viz.ai has raised $150 million.
WHAT IT DOES
The Viz.ai platform harnesses AI to automatically review CT scans and search for suspected large vessel occlusions, a common type of stroke. Once identified, the platform alerts all members of the stroke team to triage the patient.
RapidAI Expands AI-powered Vascular Imaging Globally
March 16, 2021 RapidAI, a leader in advanced cerebrovascular imaging, announced record-shattering 2020 milestones for the company and industry, as well as an expansion of its scope into the larger vascular market. As RapidAI momentum built around the world, in addition to new products, partnerships, and awards, 2020 saw the company expand from stroke to aneurysm and lay the groundwork for other vascular diseases, both acute and non-acute. The RapidAI footprint grew to over 60 countries, with its technology utilized in over 1,800 hospitals.
RapidAI offers widely used advanced cerebrovascular imaging products for patient care, research, and clinical trials across the globe. RapidAI clinical products help save lives. In 2020, RapidAI workflow and messaging technologies helped stroke teams save time, and RapidAI analytics and business intelligence products began helping stroke networks reduce costs and improve patient outcomes.